Healthcare stocks that could be poised for a rebound

Health care (NYSEARCA:XLV) is the most oversold global sector, according to BofA.

The sector was down 6.3% from its 200-day moving average in U.S. dollar terms, followed by energy (XLE) and biotechnology (XBI), -6.2% and -6.1% respectively.

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV) is down 2.5% year-to-date, while the Vanguard Health Care Index Fund ETF Shares (VHT) is down 3.4% year-to-date.

Below are health care stocks that are oversold – measured by their relative strength index – but still rated “hold” or above by Seeking Alpha Quant metrics.

A stock is considered oversold when its Relative Strength Index (or RSI) dips below 30. This index measures the length of recent price changes to evaluate their “oversold” or “overbought” conditions. Stocks with an RSI below 30 may indicate that stocks are poised for a rebound.

Seeking Alpha's Quant system consistently outperforms the S&P 500 (SP500), driven by powerful computer processing and SA's special 'Quantamental' analysis. It awards grades to stocks based on collective value, growth, profitability, earnings per share revisions, and price momentum metrics.

• OPKO Health (OPK) – Quant rating: 3.73; RSI: 30
• LogicMark (LGMK) – Quant rating: 3.42; RSI: 22
• Theriva Biologics (TOVX) – Quant rating: 3.37; RSI: 23
• Windtree Therapeutics (WINT) – Quant rating: 3.35; RSI: 28
• cbdMD (YCBD) – Quant rating: 3.29; RSI: 25
• UnitedHealth Group (UNH) – Quant rating: 3.18; RSI: 25
• Vertex Pharmaceuticals (VRTX) – Quant rating: 3.15; RSI: 27
• Dyadic International (DYAI) – Quant rating: 3.14; RSI: 29
• X4 Pharmaceuticals (XFOR) – Quant rating: 3.07; RSI: 21
• Applied DNA Sciences (APDN) – Quant rating: 3.06; RSI: 24
• HealthStream (HSTM) – Quant rating: 3.01; RSI: 28
• Phathom Pharmaceuticals (PHAT) – Quant rating: 2.87; RSI: 25
• CollPlant Biotechnologies (CLGN) – Quant rating: 2.86; RSI: 23
• Krystal Biotech (KRYS) – Quant rating: 2.82; RSI: 27
• Sera Prognostics (SERA) – Quant rating: 2.80; RSI: 18
• Lantheus Holdings (LNTH) – Quant rating: 2.78; RSI: 28
• Axogen (AXGN) – Quant rating: 2.76; RSI: 26
• Capricor Therapeutics (CAPR) – Quant rating: 2.75; RSI: 29
• Citius Pharmaceuticals (CTXR) – Quant rating: 2.72; RSI: 30
• Alzamend Neuro (ALZN) – Quant rating: 2.71; RSI: 24